Oviva

With all the recent conversation around weight loss medications and patient access in the UK, we've just published a blog exploring the impact of Wegovy, featuring inspiring patient stories from our Tier 3 Weight Management Programme. Our holistic approach combines medical, dietetic, physical activity, and psychological support to help patients achieve sustainable weight loss. The blog also outlines the programme’s eligibility criteria and referral process. Check out the blog here to learn more about how we're supporting patients on their journey to better health: https://lnkd.in/ezhh3NRw

'𝗛𝗮𝗽𝗽𝘆 𝗙𝗿𝗶𝗱𝗮𝘆' is how the Deputy Chief of Mission of the German Embassy in Paris closed her warm welcoming today at the 𝗗𝗜𝗚𝗔 & 𝗣𝗘𝗖𝗔𝗡 𝗲𝘃𝗲𝗻𝘁 event. 🇫🇷 🇩🇪 And I'd say the subsequent conversations showed that the glass for #DTx in Europe is more than half full: While it’s not yet time to be fully happy with the frameworks in either country, today’s event clearly demonstrated the strong commitment to supporting patients with digital therapeutics across EU borders. • #DiGA and #PECAN offer valuable opportunities for mutual learning: France excels in integrating telemonitoring solutions into its healthcare system, while Germany has demonstrated the feasibility and impact of DTx in ours. • Close collaboration between governments and HTA bodies is essential to harmonize requirements for DTx, particularly regarding evidence standards. The recent case of HelloBetter highlights this need, as evidence deemed sufficient for DiGA did not result in a positive decision in PECAN. Clear and transparent guidelines are crucial to bridge these gaps. • The European Taskforce for Harmonization of DMD hosted by EIT Health will publish first results of their work by end of this year. An important forum to work on a convergent European framework for the mid- to longterm future while the national pathways evolve and hopefully succeed in providing scalable access to patients in need. Let me know what you think is most critical to achieve a successful European market for digital medical devices. 𝘏𝘢𝘱𝘱𝘺 𝘍𝘳𝘪𝘥𝘢𝘺 𝘦𝘷𝘦𝘳𝘺𝘰𝘯𝘦! Many thanks to Dr. Lars Hunze, and Spitzenverband Digitale Gesundheitsversorgung for the opportunity to bring in the industry perspective today. Louisa Stüwe Vincent Vercamer Stephane Tholander Dr. Jan Hensmann Jérôme Fabiano

After nearly 10 years at Oviva, explaining to people 𝗪𝗛𝗔𝗧 we do has never been an issue for me. We are here to provide the most accessible and effective care to those living with weight-related conditions. Simple! But when it comes to the 𝗛𝗢𝗪, that has always felt a little trickier to explain. It’s easy to say what we are not - we are not a fad, one size fits all, set diet for weight loss. The Oviva method has been used to treat over 700k individual patients to date, all with individual #genetics, #psychology, #gut #hormones, needs, #goals, lives, #routines, #cultures and health situations, and yet this method is designed to suit them all. The answer lies in #behaviour #change. Every single management guideline and position statement produced in obesity globally has behaviour change at the foundation and core of its #treatment #paradigms and for good reason. Without effective behaviour change, patients stop taking #medications, short term diets are not maintained, and dietary quality worsens leading to potential malnutrition. Put simply, not a single #obesity therapy we have works well in the absence of effective behaviour change. The Oviva method outlines how we do behaviour change well, with the interplay of digital tools and healthcare professionals, to ensure each patient accesses the right information, strategies, tools and support to achieve their goals. And the results are telling; not just in our published clinical outcomes across #obesity, pre-diabetes, type 2 #diabetes, #NAFLD and #hypertension but also in our patient feedback and stories and long-standing partnerships with payors and regulators across the UK, Germany and Switzerland (references in comments). Want to join our mission at Oviva? Check out our open positions on https://lnkd.in/eZrzJZNW

Oviva Direkt turned 3 today! We are proud of our accomplishments - here a bit more on how it became our leading product. Our core principles stayed the same throughout: 🎯 Patients first, always. Oviva´s focus has always been on delivering real value to patients. Our patients completing prescriptions in the last 3 months averaged 4.6% weight loss after 12 weeks and 6.9% after 24 weeks. In 2022, this was 3.7% and 4.3%, respectively. A massive improvement, driven by more engagement and a better product. We’re proud to be one of the highest-rated DiGA in the app stores. That speaks to the trust our users place in us. Our development will never stop as we know there’s always more to do for our patients. 🦺 Regulatory compliance - an obligation to great patient care. You can’t care for patients or build trust if you do not care for safety and data privacy. Navigating the DiGA space requires strict, non-negotiable adherence to patient safety and data regulations. These standards ensure top-quality care and help us build strong competitive advantages. We’ve invested over €3m to comply with evolving BfArM standards, and are continuously engaging in regulatory processes - with about 6 interactions with the regulator a year - to launch impactful feature updates for our patients. Simultaneously, we engage with key stakeholders like gematik GmbH to ensure our products simplify the lives of doctors and patients, such as through integration into Germany's electronic health records. 🔎 Continuing to invest in evidence. Our commitment doesn’t end with reimbursement of our first Oviva Direkt study. We believe in generating evidence across the lifecycle of our interventions and will shortly complete a longer-term RCT trial aiming to extend our reimbursed population (link in comments). Additionally, we recently celebrated the successful completion of recruitment for a study on our second DiGA (link in comments), with more exciting developments on the horizon. Our focus remains on continuous improvement—ensuring our patients receive the best care possible through AI-based innovation and rigorous standards. Thank you to our awesome patients, all our referrers and partners for being part of this journey! And a huge thank you to our team for making it possible. #patientsfirst #digitalhealth #digitaltherapeutics #DiGA #healthcareinnovation

Great innovations are happening in digital health in Europe and NHS England is showing what can be done: For weight loss medications, they negotiated a great price of c. 80 GBP/month for #Wegovy (c. 90% less than US list prices), as they could negotiate for a nation. They embraced digital services around it, for instance, Oviva's Tier 3 Weight Management Service. Both the medication and our services were assessed by NICE as cost effective for patients with BMI over 35. Now, we can offer it nationwide for eligible patients, including those who have medications fully reimbursed by the NHS. Below is some coverage on this in the Daily Express. Healthcare moves slowly, for both good and bad reasons. When it does move, it can transform many lives for the better. I will continue focusing on the positive changes I see working in and improving healthcare. Let me know if you see more topics to talk about! https://lnkd.in/eW_W3JSs #nhs #obesity #wegovy #digitalhealth

🎉 We’re finalists in two categories at the LaingBuisson Awards 2024! 🎉 We’re proud to announce that Oviva has been shortlisted for two awards at the upcoming LaingBuisson Awards 2024: 1️⃣ Health Tech Product of the Year –  Our Oviva app has been acknowledged for its innovative, digitally enabled approach to weight management and patient experience. Supporting the NHS, the app uses leading AI technology and empowers patients to develop sustainable behaviour change with the guidance of our clinical team. 2️⃣ Public Private Partnership – Recognising our partnership with Norfolk and Waveney ICB, where we successfully delivered our digital Tier 3 Weight Management service. Our service increased accessibility, breaking down barriers to care for hard-to-reach populations. We look forward to the awards on the 21st November and are excited to continue working to drive better health outcomes for patients across the UK. 🤞 👉Learn more at www.oviva.com/uk/en/ #DigitalHealth #LaingBuissonAwards2024 #Oviva #NHS #WeightManagement

This week, JAMA published real world data from liraglutide (#Saxenda) and #Semaglutide (#Wegovy) in the US showing much poorer outcomes at 1 year (6% weight loss) compared to those published in the controlled clinical trials. #Reimbursement was a key issue highlighted in the paper with those receiving continuous reimbursement achieving nearly double the weight loss of those needing to self-fund. They also called for greater understanding of the key factors causing people to discontinue therapy. Oviva recognises that weight loss medications can only work within an effective service for those living with obesity - which is accessible through reimbursement and able to support people beyond the medications and side effects with #psychology, #dietary and physical activity support all key components. This is what leads to #retention and clinical trial worthy #outcomes at a year. Oviva achieves 13% weight loss in the 1st year in its reimbursed weight loss medication patients across the UK and Switzerland and doubles retention compared to the published real world data: https://lnkd.in/eRx72hsX

Free CPD webinar for GPs 🚀 Boost your knowledge on managing obesity 🚀 Join us for a free webinar on “Understanding new obesity treatments: Everything GPs need to know about weight loss medication”. During this session, our experienced panel will cover: →The scale and complexity of obesity in England →Why obesity deserves to be treated, not dismissed →The effectiveness of weight loss medications: Data and patient success stories →Practical guidance on prescribing and managing side effects Interested? We thought you might be! Sign up today via Eventbrite 🎟️

Oviva’s Tier 3 Weight Management Programme is now available across England on the NHS, offering free weight loss injections (GLP-1s) to eligible patients. This announcement is a major step towards tackling the obesity crisis. Obesity is the second leading cause of cancer behind smoking, the primary cause of Type 2 diabetes, and is associated with over 200 other conditions, including heart attacks and strokes. This announcement offers a lifeline to people who have been unable to access obesity treatment. www.oviva.com/uk/en/ #HealthcareForAll #WeightManagement #NHS #HealthEquity #Oviva

We are excited to announce that Oviva can now provide weight loss injections (GLP-1s) for free on the NHS as part of its Tier 3 weight management programme. Eligible patients across England can be referred by their GP to access Oviva’s service. This major development offers hope for the 4.2 million people eligible for specialist weight management support. We’re committed to reversing the two-tier system emerging in our NHS, ensuring everyone, not just those who can afford to pay privately, can access these potentially lifesaving, NICE-approved medications. Check if you’re eligible and learn more at www.oviva.com/uk/en/ #RightToChoose #WeightManagement #HealthcareForAll #Oviva